• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Homology Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/9/24 7:06:23 AM ET
    $FIXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FIXX alert in real time by email
    8-K
    false000166199800016619982024-05-092024-05-09

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 09, 2024

     

     

    Q32 Bio Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38433

    47-3468154

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    830 Winter Street

     

    Waltham, Massachusetts

     

    02451

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 781 999-0232

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

     

    QTTB

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 9, 2024, Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2024 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

     

     

    99.1

    Press Release issued by Q32 Bio Inc. on May 9, 2024

     

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Q32 BIO INC.

     

     

     

     

    Date:

    May 9, 2024

    By:

    /s/ Jodie Morrison

     

     

    Name:

    Title:

    Jodie Morrison
    Chief Executive Officer

     


    Get the next $FIXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FIXX

    DatePrice TargetRatingAnalyst
    7/28/2023$9.00 → $1.50Outperform → Neutral
    Robert W. Baird
    2/28/2022$30.00 → $20.00Buy
    HC Wainwright & Co.
    2/22/2022$25.00 → $9.00Buy
    B of A Securities
    2/22/2022$35.00 → $29.00Neutral
    BTIG Research
    2/22/2022Outperform → Sector Perform
    RBC Capital Mkts
    2/22/2022$25.00 → $15.00Buy
    Chardan Capital
    2/22/2022$35.00 → $29.00Buy
    BTIG
    2/22/2022$30.00 → $4.00Outperform → Sector Perform
    RBC Capital
    More analyst ratings

    $FIXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alloway Paul sold $6,488 worth of shares (268 units at $24.21), decreasing direct ownership by 9% to 2,596 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:03:07 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Michaud Charles Jr sold $1,815 worth of shares (75 units at $24.20), decreasing direct ownership by 7% to 927 units (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      4/23/24 5:00:03 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tzianabos Arthur

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      3/27/24 5:43:06 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Homology Medicines Inc.

      424B3 - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:26:07 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Homology Medicines Inc.

      10-Q - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:18:33 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Q32 Bio Inc. (0001661998) (Filer)

      5/9/24 7:06:23 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Leadership Updates

    Live Leadership Updates

    See more
    • Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

      - ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 - BEDFORD, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today the appointment of gene therapy expert Beverly Davidson, Ph.D., as Chair of the Company's Scientific Advisory Board, on which she has served since 2018. Dr. Davidson is the Director of the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, the Chief Scientific Strategy Officer, and holds the Arthur V. Meigs Chair in Pediatrics at the Children's Hospital of Philadelphia. She was also recently named Pr

      8/5/21 8:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference

      BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the "Gene Editing Corporate Panel" during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET. The live webcast presentation will be accessible on Homology's website in the Investors section, and the webcast replay will be available on the website for 90 days following the presentation. About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients

      3/2/23 7:30:54 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Homology Medicines to Participate at Upcoming Conferences

      BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (NASDAQ:FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT"Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic" panel featuring Dr. Seymour on October 11 at 4:00 p.m. PT"New Business Models for Manufacturing Investment" panel featuring Arthur Tzianabos, Ph.D., Chairman of the Board of Homology, on October 12 at 3:15 p.m. PT

      10/6/22 8:30:27 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures

      SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

      9/27/22 8:15:00 AM ET
      $AKUS
      $CINC
      $FIXX
      $IONS
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Homology Medicines downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Homology Medicines from Outperform to Neutral and set a new price target of $1.50 from $9.00 previously

      7/28/23 7:17:02 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Homology Medicines with a new price target

      HC Wainwright & Co. reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $20.00 from $30.00 previously

      2/28/22 7:12:58 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B of A Securities reiterated coverage on Homology Medicines with a new price target

      B of A Securities reiterated coverage of Homology Medicines with a rating of Buy and set a new price target of $9.00 from $25.00 previously

      2/22/22 10:12:45 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Financials

    Live finance-specific insights

    See more
    • Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner

      Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business  Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programs and genetic medicines platform Oxford Biomedica to invest $50 million to fund the growth of Oxford Biomedica Solutions LLC and will own 80%, with Homology Medicines to own 20%; Homology Medicines to secure preferred key customer status Dr. Roch Doliveux to become Interim CEO of Oxford Biomedica and John Dawson to retire as CEO and remain a Board Director of Oxford Biomedica Oxford Biomedica and Homology Medicines to host webcasts t

      1/28/22 2:30:00 AM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FIXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Homology Medicines Inc. (Amendment)

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      5/13/24 5:34:55 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/4/24 8:33:33 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Homology Medicines Inc.

      SC 13D - Q32 Bio Inc. (0001661998) (Subject)

      4/1/24 9:52:41 PM ET
      $FIXX
      Biotechnology: Pharmaceutical Preparations
      Health Care